NCT05270954 - Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2 | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

April 25, 2022

Study Completion Date

July 24, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

Betuvax-CoV-2

Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)

DRUG

Placebo

Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)

Trial Locations (3)

"Eco-Safety R&D center", Saint Petersburg

Department of Vaccinology, Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, Saint Petersburg

Center of professional medicine, Perm